Figure S8.
Dissecting dynamics of phosphoinositide pools with drugs acting on PKC or PI4KІІІα.(A) Time course of heterologous nFRETeff between P4M-CFP and Lyn-YFP in control cells and cells preincubated in 2 µM BIM during stimulation with a very low concentration of Oxo-M (10 nM, gray bar). (B) Increase of PM PtdIns4P concentration by application of 5 µM PMA (orange bar) with or without pretreatment with A1 (green shading), a specific PI4KІІІα inhibitor. (C) Pretreatment with 30 nM A1 initiated a loss of PM PtdIns4P, but 10 nM Oxo-M still stimulated PM PtdIns4P production. (D) Control cells and cells preincubated in 2 µM BIM expressing PtdIns(4,5)P2 FRET probes showed regeneration during receptor activation by 10 µM Oxo-M.

Dissecting dynamics of phosphoinositide pools with drugs acting on PKC or PI4KІІІα. (A) Time course of heterologous nFRETeff between P4M-CFP and Lyn-YFP in control cells and cells preincubated in 2 µM BIM during stimulation with a very low concentration of Oxo-M (10 nM, gray bar). (B) Increase of PM PtdIns4P concentration by application of 5 µM PMA (orange bar) with or without pretreatment with A1 (green shading), a specific PI4KІІІα inhibitor. (C) Pretreatment with 30 nM A1 initiated a loss of PM PtdIns4P, but 10 nM Oxo-M still stimulated PM PtdIns4P production. (D) Control cells and cells preincubated in 2 µM BIM expressing PtdIns(4,5)P2 FRET probes showed regeneration during receptor activation by 10 µM Oxo-M.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal